This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
by Zacks Equity Research
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
by Zacks Equity Research
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
BEAMNegative Net Change FOLDPositive Net Change ZTSNegative Net Change ANIPPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
by Zacks Equity Research
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
VRTXNegative Net Change ANIPPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs pharmaceuticals
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
by Zacks Equity Research
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change ARGXPositive Net Change
biotechs earnings
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
by Zacks Equity Research
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
JAZZNegative Net Change ANIPPositive Net Change AXSMNegative Net Change NTLANegative Net Change
biotechs earnings
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
by Zacks Equity Research
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
TGTXPositive Net Change ANIPPositive Net Change NTLANegative Net Change ARQTNegative Net Change
biotechs earnings
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
BEAMNegative Net Change NBIXPositive Net Change FOLDPositive Net Change XENENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
by Zacks Equity Research
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
GSKPositive Net Change ALKSPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
GSKPositive Net Change PFENegative Net Change MRKPositive Net Change MRNANegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
ANIPPositive Net Change CRSPNegative Net Change IMCRNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
VRTXNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs crispr earnings gene-editing gene-therapy medical
Intellia Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
NTLA's third-quarter results are likely to reflect progress on the CRISPR pipeline, with focus on ATTR studies and progress in HAE therapy filing.
REGNNegative Net Change ANIPPositive Net Change NTLANegative Net Change IMCRNegative Net Change
biotechs
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
by Kanishka Das
Let's look at five pharma and biotech companies, PFE, AMGN, AZN, VTRS and MRNA, which are scheduled to release their third-quarter 2025 results this week.
AZNPositive Net Change PFENegative Net Change AMGNPositive Net Change MRNANegative Net Change VTRSNegative Net Change
biotechs pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
ZYME, NKTR, ANIP, and PCRX are poised for potential Q3 earnings surprises as the biotech sector shows strong momentum.
NKTRNegative Net Change PCRXPositive Net Change ANIPPositive Net Change ZYMENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
by Zacks Equity Research
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
by Ekta Bagri
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
BEAMNegative Net Change FOLDPositive Net Change ANIPPositive Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
by Zacks Equity Research
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
BEAMNegative Net Change AGIONegative Net Change ANIPPositive Net Change NTLANegative Net Change
biotechs earnings
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXPositive Net Change AMGNPositive Net Change EWPositive Net Change OHIPositive Net Change ABBVPositive Net Change CTREPositive Net Change ENSGPositive Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
ALNYNegative Net Change RHHBYPositive Net Change BEAMNegative Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
by Zacks Equity Research
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
GSKPositive Net Change ALKSPositive Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
by Zacks Equity Research
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
ALKSPositive Net Change INSMNegative Net Change HOWLNegative Net Change
biotechs earnings medical
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PFENegative Net Change TBPHNegative Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
by Zacks Equity Research
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
BIIBNegative Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals